263 related articles for article (PubMed ID: 32295160)
1. Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type.
Eyileten C; Postula M; Jakubik D; Toma A; Mirowska-Guzel D; Patti G; Renda G; Siller-Matula JM
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32295160
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.
Capodanno D; Di Maio M; Greco A; Bhatt DL; Gibson CM; Goette A; Lopes RD; Mehran R; Vranckx P; Angiolillo DJ
J Am Heart Assoc; 2020 Aug; 9(16):e017212. PubMed ID: 32805186
[TBL] [Abstract][Full Text] [Related]
3. A network meta-analysis of the antithrombotic strategies in patients with atrial fibrillation and percutaneous coronary interventions: Focus on bleeding.
Dimitriadis K; Soulaidopoulos S; Doundoulakis I; Iliakis P; Tsiachris D; Tsioufis P; Beneki E; Sakalidis A; Pagkalidou E; Tsiamis E; Tsioufis K
Hellenic J Cardiol; 2023; 73():69-72. PubMed ID: 37080485
[TBL] [Abstract][Full Text] [Related]
4. Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF): Rationale and design of the prospective randomized parallel-group, open-label, blinded-endpoint, superiority, multicenter-trial of a triple therapy versus a dual therapy in patients with Atrial Fibrillation and Acute Coronary Syndrome undergoing coronary stenting.
Riesinger L; Strobl C; Leistner DM; Gori T; Akin I; Mehr M; Kellnar A; Mahabadi AA; Bogossian H; Block M; Edelmann F; Sarafoff N; Sibbing D; Ince H; Rassaf T; Mansmann U; Mehilli J; Kääb S; Hausleiter J; Massberg S; Wakili R
Int J Cardiol Heart Vasc; 2021 Aug; 35():100810. PubMed ID: 34258380
[TBL] [Abstract][Full Text] [Related]
5. Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention: a network meta-analysis.
Al Said S; Alabed S; Kaier K; Tan AR; Bode C; Meerpohl JJ; Duerschmied D
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD013252. PubMed ID: 31858590
[TBL] [Abstract][Full Text] [Related]
6. Optimisation of oral anticoagulants for patients with atrial fibrillation within 12 months after percutaneous coronary intervention: A
Wang S; Liu Y; Wang L; Zuo H; Tian Y; Wang Y; Yin D; Zhang H; Tian Y
Int J Cardiol Heart Vasc; 2021 Oct; 36():100850. PubMed ID: 34401468
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of NOAC vs. VKA in patients treated by PCI: a retrospective study of the FRANCE PCI registry.
Durand E; Verrez T; Gillibert A; Levesque T; Barbe T; Koning R; Motreff P; Eltchaninoff H; Collet JP; Rangé G
Front Cardiovasc Med; 2023; 10():1320001. PubMed ID: 38292452
[TBL] [Abstract][Full Text] [Related]
8. Two Approaches to Triple Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Treated with Percutaneous Coronary Intervention: Which Is More Efficient and Safer?
Bachorski W; Bychowski J; Gruchała M; Jaguszewski M
Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835798
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of dual versus triple antithrombotic therapy (DAT vs TAT) in patients with atrial fibrillation following a PCI: a systematic review and network meta-analysis.
Altoukhi RM; Alshouimi RA; Al Rammah SM; Alzahrani MY; Almutairi AR; Alshehri AM; Alfayez OM; Al Yami MS; Almohammed OA
BMJ Open; 2020 Sep; 10(9):e036138. PubMed ID: 32994232
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of direct oral anticoagulants compared to Vitamin K antagonists postpercutaneous coronary interventions in patients with atrial fibrillation: A systematic review and meta-analysis.
Agasthi P; Lee JZ; Pujari SH; Tseng AS; Shipman J; Almader-Douglas D; Ashraf H; Mookadam F; Fortuin FD; Beohar N; Arsanjani R; Mulpuru S
J Arrhythm; 2020 Apr; 36(2):271-279. PubMed ID: 32256873
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of dual versus triple antithrombotic therapy in Patients with atrial fibrillation undergoing percutaneous coronary intervention: A meta-analysis.
Moustafa A; Khan MS; Marei A; Alsamman MA; Baig M; Saad M
Avicenna J Med; 2020; 10(4):232-240. PubMed ID: 33437696
[TBL] [Abstract][Full Text] [Related]
12. Network Meta-Analysis of Initial Antithrombotic Regimens After Left Atrial Appendage Occlusion.
Carvalho PEP; Gewehr DM; Miyawaki IA; Nogueira A; Felix N; Garot P; Darmon A; Mazzone P; Preda A; Nascimento BR; Kubrusly LF; Cardoso R
J Am Coll Cardiol; 2023 Oct; 82(18):1765-1773. PubMed ID: 37611779
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of non-vitamin K antagonist versus vitamin K antagonist oral anticoagulants in the prevention and treatment of thrombotic disease in active cancer patients: a systematic review and meta-analysis of randomized controlled trials].
Wang CX; Wu D; Yang PP; Wu QH
Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Aug; 48(8):689-696. PubMed ID: 32847326
[No Abstract] [Full Text] [Related]
14. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials.
Golwala HB; Cannon CP; Steg PG; Doros G; Qamar A; Ellis SG; Oldgren J; Ten Berg JM; Kimura T; Hohnloser SH; Lip GYH; Bhatt DL
Eur Heart J; 2018 May; 39(19):1726-1735a. PubMed ID: 29668889
[TBL] [Abstract][Full Text] [Related]
15. Comparative safety review of antithrombotic treatment options for patients with atrial fibrillation undergoing percutaneous coronary intervention.
Erbay MI; Pyrpyris N; Susarla S; Ulusan S; Mares AC; Wilson TP; Lee D; Sood A; Gupta R
Expert Opin Drug Saf; 2024 Feb; 23(2):149-160. PubMed ID: 38214282
[TBL] [Abstract][Full Text] [Related]
16. Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis.
Brunetti ND; Tarantino N; De Gennaro L; Correale M; Santoro F; Di Biase M
Open Heart; 2018; 5(2):e000785. PubMed ID: 30018775
[TBL] [Abstract][Full Text] [Related]
17. Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial.
Joosten LPT; van Doorn S; van de Ven PM; Köhlen BTG; Nierman MC; Koek HL; Hemels MEW; Huisman MV; Kruip M; Faber LM; Wiersma NM; Buding WF; Fijnheer R; Adriaansen HJ; Roes KC; Hoes AW; Rutten FH; Geersing GJ
Circulation; 2024 Jan; 149(4):279-289. PubMed ID: 37634130
[TBL] [Abstract][Full Text] [Related]
18. Optimal antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention: triple therapy is too much!
Jacobs MS; Tieleman RG
Neth Heart J; 2018 Jun; 26(6):334-340. PubMed ID: 29740755
[TBL] [Abstract][Full Text] [Related]
19. Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-Analysis.
Skaistis J; Tagami T
PLoS One; 2015; 10(9):e0137444. PubMed ID: 26383245
[TBL] [Abstract][Full Text] [Related]
20. Is triple antithrombotic therapy a safe option in patients with AF who receive drug-eluting stents?: a review article.
Alshahrani A; O'Nunain S
Egypt Heart J; 2023 Aug; 75(1):74. PubMed ID: 37639078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
